# A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration

> **NCT02873351** · PHASE2 · WITHDRAWN · sponsor: **Snyder, Robert W., M.D., Ph.D., P.C.**

## Conditions studied

- Age-related Macular Degeneration

## Interventions

- **DRUG:** carbidopa-levodopa 25-100 mg
- **DRUG:** placebo for carbidopa-levodopa 25-100 mg

## Key facts

- **NCT ID:** NCT02873351
- **Lead sponsor:** Snyder, Robert W., M.D., Ph.D., P.C.
- **Sponsor class:** INDIV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-09
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Decided to do studies in patients with AMD
- **Last updated:** 2019-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02873351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02873351, "A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02873351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*